Includes: background on nicotine pharmacology; corporate relationship between British-American Tobacco Co. and Brown and Williamson Tobacco Co.; FDA letters to tobacco manufacturers; bibliography of industry-funded research; marketing of cigarettes and smokeless tobacco in the U.S.; citizen petitions and submitted comments; statements by David A. Kessler, M.D., Commissioner of Food and Drugs, on nicotine-containing cigarettes and on the control and manipulation of nicotine in cigarettes; and remarks by David A. Kessler, M.D., The Samuel Rubin Program, The Columbia University School of Law, March 8, 1995.

Advances in pharmacogenomics and proteomics, along with the introduction of recombinant DNA technology, have expanded the applications of pharmacology to encompass a range of disciplines. Biomedical researchers, protein specialists, and molecular biologists are all involved in the development and delivery of novel drugs. Therefore, students in a va